A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan

Last updated: January 27, 2025
Sponsor: AbbVie
Overall Status: Completed

Phase

N/A

Condition

Leukemia

Chronic Lymphocytic Leukemia

Lymphoproliferative Disorders

Treatment

N/A

Clinical Study ID

NCT06362044
P24-120
  • Ages > 18
  • All Genders

Study Summary

Most cases of Chronic lymphocytic leukemia (CLL) remain an incurable disease with the goal of therapy being to improve quality of life and to prolong survival. This study will evaluate the participant's related outcomes and experience of CLL in adult participants who are treated in the Japan.

Study participants will receive oral treatments of Venetoclax±Rituximab for CLL as prescribed by their study doctor in accordance with approved local label. Adult participants prescribed various treatments Venetoclax±Rituximab will be enrolled. Around 89 participants will be enrolled in the study in sites in Japan.

Participants will receive oral venetoclax tablets ± intravenously (IV) infused rituximab treatments for CLL according to the approved local label. The overall study duration will be 27 months.

There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosed with relapsed/refractory (2 Line [2L]+) chronic lymphocytic leukemia (CLL)in Japan based on International Workshop on Chronic Lymphocytic Leukemia (iwCLL)criteria at the time of informed consent (IC).

  • Treatment with Venetoclax±Rituximab for 24 months who are not treated with any otherconcurrent CLL treatment.

  • Expected to visit the hospital at + 3 months after treatment withVenetoclax±Rituximab for 24 months.

Exclusion

Exclusion Criteria:

  • No data on information on the start and end dates or continuation of treatment withVenetoclax.

  • Participating in other clinical trials.

Study Design

Total Participants: 89
Study Start date:
June 07, 2023
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • National Cancer Center Hospital East /ID# 265970

    Kashiwa, Chiba 277-8577
    Japan

    Site Not Available

  • National Cancer Center Hospital East /ID# 265970

    Kashiwa-shi, Chiba 277-8577
    Japan

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.